AVBP vs EG · $1.39B cap vs P/E 17, rev $8.03B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus Everest Group Ltd (EG) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
Everest Group Ltd (EG) is a insurance - reinsurance company listed on US.
AVBP does not have a complete income-statement cache yet.
Latest reported EG revenue for 2026-06-30 was $8.03B. Net income was $1.21B. Revenue was up 97.4% from 2026-03-31 to 2026-06-30. EG currently screens at market cap $14.52B and trailing P/E 17.2.
AVBP currently screens at market cap $1.39B. EG currently screens at market cap $14.52B and trailing P/E 17.2.
Not investment advice. Open the AVBP and EG stock pages for the full models.
Not investment advice.